Landos Biopharma (NASDAQ: LABP)
Some price data may be temporarily unavailable.
Landos Biopharma Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Landos Biopharma Company Info
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of novel, oral, once-daily therapeutics for patients with certain immunology diseases. It offers NX-13, a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. The firm's preclinical candidates include LABP-73, LABP-66, and LABP-69. The company was founded by Josep Bassaganya-Riera in January 2017 and is headquartered in Blacksburg, VA.
News & Analysis
No articles found.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.